ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives
Commentary on: Bangalore S, Ogedegbe G, Gyamfi J, et al.. Outcomes with angiotensin-converting enzyme inhibitors vs other antihypertensive agents in hypertensive blacks. Am J Med 2015;128:1195–203. Context Hypertension affects one-third of the world's population and remains a leading cause of myocardial infarction, stroke, heart failure, renal failure and death. Although hypertension control has improved,1 the prevalence is increasing due to an ageing population, rising obesity and a shift towards western lifestyles and disease patterns in low-income and middle-income countries. Hypertension is now also a major contributor to heart failure in low-income countries.2 Furthermore, control of blood pressure (<140/90 mm Hg) is achieved in only half of patients.1 In the recent landmark Systolic Blood Pressure Intervention Trial (SPRINT) a systolic blood pressure target of 120 vs 140 mm Hg led to a considerable reduction in cardiovascular outcomes and death.3 Therefore, a pressing worldwide concern...
Source: Evidence-Based Medicine - Category: Internal Medicine Authors: Lund, L. H. Tags: EBM Prognosis, Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Obesity (nutrition), Ischaemic heart disease, Renal medicine, Drugs: musculoskeletal and joint diseases, Health education Source Type: research
More News: African Health | Cardiology | Cardiovascular | Eating Disorders & Weight Management | Education | Epidemiology | Health | Heart | Heart Attack | Heart Disease | Heart Failure | Hypertension | Internal Medicine | Ischemic Stroke | Nutrition | Obesity | Renal Failure | Stroke | Study | Universities & Medical Training